ATE408407T1 - Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch - Google Patents
Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauchInfo
- Publication number
- ATE408407T1 ATE408407T1 AT03743001T AT03743001T ATE408407T1 AT E408407 T1 ATE408407 T1 AT E408407T1 AT 03743001 T AT03743001 T AT 03743001T AT 03743001 T AT03743001 T AT 03743001T AT E408407 T1 ATE408407 T1 AT E408407T1
- Authority
- AT
- Austria
- Prior art keywords
- related diseases
- inhibitors
- drug
- treat substance
- substance use
- Prior art date
Links
- 208000011117 substance-related disease Diseases 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 108010002386 Interleukin-3 Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010013663 drug dependence Diseases 0.000 abstract 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 abstract 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 206010048010 Withdrawal syndrome Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000779 depleting effect Effects 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addiction (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35965102P | 2002-02-27 | 2002-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE408407T1 true ATE408407T1 (de) | 2008-10-15 |
Family
ID=27766119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03743001T ATE408407T1 (de) | 2002-02-27 | 2003-02-26 | Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050203098A1 (enExample) |
| EP (1) | EP1490067B1 (enExample) |
| JP (1) | JP2005530696A (enExample) |
| AT (1) | ATE408407T1 (enExample) |
| AU (1) | AU2003209933A1 (enExample) |
| CA (1) | CA2477726A1 (enExample) |
| DE (1) | DE60323613D1 (enExample) |
| ES (1) | ES2314223T3 (enExample) |
| WO (1) | WO2003072106A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL208484B1 (pl) | 2001-07-06 | 2011-05-31 | Penwest Pharmaceuticals Company | Sposoby wytwarzania preparatów oksymorfonu o przedłużonym uwalnianiu |
| US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
| CN1551770A (zh) | 2001-07-06 | 2004-12-01 | ������ҩ������˾ | 羟吗啡酮控释制剂 |
| ATE465731T1 (de) | 2003-10-23 | 2010-05-15 | Ab Science | 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer |
| SI2366703T1 (sl) | 2007-02-13 | 2014-10-30 | Ab Science | Polimorfna oblika 2-amino (nitroaril) tiazolnega derivata |
| CN105974131B (zh) * | 2016-06-16 | 2017-12-26 | 武汉大学 | c‑Kit作为药物成瘾治疗靶点的应用 |
| US20220079950A1 (en) * | 2018-12-31 | 2022-03-17 | The Regents Of The University Of California | Therapeutic combinations as antidotes for organophosphate exposure |
| CN112575073B (zh) * | 2019-09-30 | 2022-10-04 | 武汉大学 | c-Kit作为成瘾诊断及监测标志物的应用 |
| CN112569238A (zh) * | 2019-09-30 | 2021-03-30 | 武汉大学 | 伊马替尼及其衍生物与镇痛药联合用药或复方制剂在治疗疼痛中的应用 |
| US20240024325A1 (en) * | 2020-08-28 | 2024-01-25 | Emory University | Methods of Managing Cocaine or Other Drug Addictions |
| CN114573591B (zh) * | 2022-04-16 | 2023-04-25 | 成都施贝康生物医药科技有限公司 | 一种取代的吡咯并嘧啶化合物及其应用 |
| CN117461602B (zh) * | 2023-10-25 | 2024-10-25 | 六合熙诚(北京)信息科技有限公司 | 一种吗啡成瘾动物模型的构建方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (enExample) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag |
-
2003
- 2003-02-26 WO PCT/IB2003/001071 patent/WO2003072106A2/en not_active Ceased
- 2003-02-26 AT AT03743001T patent/ATE408407T1/de not_active IP Right Cessation
- 2003-02-26 JP JP2003570852A patent/JP2005530696A/ja not_active Withdrawn
- 2003-02-26 US US10/505,899 patent/US20050203098A1/en not_active Abandoned
- 2003-02-26 EP EP03743001A patent/EP1490067B1/en not_active Expired - Lifetime
- 2003-02-26 DE DE60323613T patent/DE60323613D1/de not_active Expired - Fee Related
- 2003-02-26 ES ES03743001T patent/ES2314223T3/es not_active Expired - Lifetime
- 2003-02-26 CA CA002477726A patent/CA2477726A1/en not_active Abandoned
- 2003-02-26 AU AU2003209933A patent/AU2003209933A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2314223T3 (es) | 2009-03-16 |
| WO2003072106A8 (en) | 2004-10-07 |
| DE60323613D1 (de) | 2008-10-30 |
| JP2005530696A (ja) | 2005-10-13 |
| WO2003072106A2 (en) | 2003-09-04 |
| US20050203098A1 (en) | 2005-09-15 |
| WO2003072106A3 (en) | 2004-04-22 |
| EP1490067A2 (en) | 2004-12-29 |
| AU2003209933A1 (en) | 2003-09-09 |
| CA2477726A1 (en) | 2003-09-04 |
| EP1490067B1 (en) | 2008-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE404202T1 (de) | Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung | |
| WO2003002114A3 (en) | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis | |
| ATE395052T1 (de) | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes | |
| ATE408407T1 (de) | Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch | |
| ATE345839T1 (de) | Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen | |
| SG169224A1 (en) | Method for treatment of tumors using nordihydrogualaretic acid derivatives | |
| ATE334693T1 (de) | Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten | |
| ATE330608T1 (de) | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen | |
| ATE388711T1 (de) | C-kithemmer zur behandlung von bakteriellen infektionen | |
| WO2003002107A3 (en) | Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) | |
| DE60234246D1 (de) | Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen | |
| WO2003004006A3 (en) | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis | |
| WO2003002105A3 (en) | Use of tyrosine kinase inhibitors for treating bone loss | |
| ATE401078T1 (de) | Die verwendung von c-kithemmern zur förderung des haarwuchses | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE343415T1 (de) | Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen | |
| WO2005115304A3 (en) | Use of c-kit inhibitors for treating fibrodysplasia | |
| WO2005102346A3 (en) | Use of c-kit inhibitors for treating fibrosis | |
| ATE382354T1 (de) | Präoperative behandlung von postoperativen schmerzen | |
| DE502004010212D1 (de) | Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse | |
| DE602004016841D1 (de) | Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen | |
| ATE407925T1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties | ||
| REN | Ceased due to non-payment of the annual fee |